Phase III trial data suggest the COVID-19 vaccine developed by Pfizer/BioNTech is effective against a variant first reported in South Africa, company officials say. Pfizer CEO Albert Bourla says the data will allow the company to file a full Biologics License Application with the FDA.
Pfizer/BioNtech: COVID-19 vaccine guards against variant
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.